Cui J, Li F, Shi Z-L. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol. 2019;17:181–92.
Masters PS. The molecular biology of coronaviruses. Adv Virus Res. 2006;66:193–292.
Wang Y, Grunewald M, Perlman S. Coronaviruses: an updated overview of their replication and pathogenesis. Methods Mol Biol. 2020;2203:1–29.
Mulabbi EN, Tweyongyere R, Byarugaba DK. The history of the emergence and transmission of human coronaviruses. Onderstepoort J Vet Res. 2021;88:e1–8.
Ksiazek TG, Erdman D, Goldsmith CS, Zaki SR, Peret T, Emery S, et al. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med. 2003;348:1953–66.
Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus ADME, Fouchier RAM. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med. 2012;367:1814–20.
Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382:727–33.
Conte C, Sogni F, Affanni P, Veronesi L, Argentiero A, Esposito S. Vaccines against coronaviruses: the state of the Art. Vaccines (Basel). 2020;8:309.
Saravanan V, Chagaleti BK, Narayanan PL, Anandan VB, Manoharan H, Anjana GV, et al. Discovery and development of COVID-19 vaccine from laboratory to clinic. Chem Biol Drug Des. 2024;103:e14383.
Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271–e2808.
Baggen J, Jacquemyn M, Persoons L, Vanstreels E, Pye VE, Wrobel AG, et al. TMEM106B is a receptor mediating ACE2-independent SARS-CoV-2 cell entry. Cell. 2023;186:3427–e344222.
Narayanan K, Chen C-J, Maeda J, Makino S. Nucleocapsid-independent specific viral RNA packaging via viral envelope protein and viral RNA signal. J Virol. 2003;77:2922–7.
Zhang B, Tian J, Zhang Q, Xie Y, Wang K, Qiu S, et al. Comparing the nucleocapsid proteins of human coronaviruses: Structure, Immunoregulation, Vaccine, and targeted drug. Front Mol Biosci. 2022;9:761173.
Yadav T, Kumar S, Mishra G, Saxena SK. Tracking the COVID-19 vaccines: the global landscape. Hum Vaccin Immunother. 2023;19:2191577.
Gong W, Parkkila S, Wu X, Aspatwar A. SARS-CoV-2 variants and COVID-19 vaccines: current challenges and future strategies. Int Rev Immunol. 2023;42:393–414.
Zeng B, Gao L, Zhou Q, Yu K, Sun F. Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis. BMC Med. 2022;20:200.
None JLXH, W YY, Z XL. Y Z, Meta-analysis investigating the relationship between clinical features, outcomes, and severity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia. Am J Infect Control. 2021;49.
Guo L, Wang Y, Kang L, Hu Y, Wang L, Zhong J, et al. Cross-reactive antibody against human coronavirus OC43 Spike protein correlates with disease severity in COVID-19 patients: a retrospective study. Emerg Microbes Infect. 2021;10:664–76.
Shrwani K, Sharma R, Krishnan M, Jones T, Mayora-Neto M, Cantoni D, et al. Detection of serum Cross-Reactive antibodies and memory response to SARS-CoV-2 in prepandemic and Post-COVID-19 convalescent samples. J Infect Dis. 2021;224:1305–15.
Dugan HL, Stamper CT, Li L, Changrob S, Asby NW, Halfmann PJ, et al. Profiling B cell immunodominance after SARS-CoV-2 infection reveals antibody evolution to non-neutralizing viral targets. Immunity. 2021;54:1290–e13037.
Borrega R, Nelson DKS, Koval AP, Bond NG, Heinrich ML, Rowland MM, et al. Cross-Reactive antibodies to SARS-CoV-2 and MERS-CoV in Pre-COVID-19 blood samples from Sierra Leoneans. Viruses. 2021;13:2325.
Flores-Alanis A, Saldaña-Ahuactzi Z, Parra-Ortega I, López-Ramírez P, Salazar-García M, Alemán-García YP, et al. Clinical characteristics of coronavirus disease (COVID-19) in Mexican children and adolescents. Viruses. 2022;14:2162.
Cortés-Sarabia K, Cruz-Rangel A, Flores-Alanis A, Salazar-García M, Jiménez-García S, Rodríguez-Martínez G, et al. Clinical features and severe acute respiratory syndrome-coronavirus-2 structural protein-based serology of Mexican children and adolescents with coronavirus disease 2019. PLoS ONE. 2022;17:e0273097.
Perrin GG, Benoit C, Saunders M. Influence of storage and heating on Sera in detection of CAEV antibodies. Small Ruminant Res. 1998;30:153–5.
Cuhadar S, Koseoglu M, Atay A, Dirican A. The effect of storage time and freeze-thaw cycles on the stability of serum samples. Biochem Med (Zagreb). 2013;23:70–7.
Frey A, Di Canzio J, Zurakowski D. A statistically defined endpoint titer determination method for immunoassays. J Immunol Methods. 1998;221:35–41.
Kesheh MM, Hosseini P, Soltani S, Zandi M. An overview on the seven pathogenic human coronaviruses. Rev Med Virol. 2022;32:e2282.
Chen B, Tian E-K, He B, Tian L, Han R, Wang S, et al. Overview of lethal human coronaviruses. Signal Transduct Target Ther. 2020;5:89.
Guruprasad L. Human coronavirus Spike protein-host receptor recognition. Prog Biophys Mol Biol. 2021;161:39–53.
Grifoni A, Sidney J, Zhang Y, Scheuermann RH, Peters B, Sette A. A sequence homology and bioinformatic approach can predict candidate targets for immune responses to SARS-CoV-2. Cell Host Microbe. 2020;27:671–e6802.
Tso FY, Lidenge SJ, Peña PB, Clegg AA, Ngowi JR, Mwaiselage J, et al. High prevalence of pre-existing serological cross-reactivity against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in sub-Saharan Africa. Int J Infect Dis. 2021;102:577–83.
Simula ER, Manca MA, Jasemi S, Uzzau S, Rubino S, Manchia P, et al. HCoV-NL63 and SARS-CoV-2 share recognized epitopes by the humoral response in Sera of people collected Pre- and during CoV-2 pandemic. Microorganisms. 2020;8:1993.
Chen Y, Zhao X, Zhou H, Zhu H, Jiang S, Wang P. Broadly neutralizing antibodies to SARS-CoV-2 and other human coronaviruses. Nat Rev Immunol. 2023;23:189–99.
Galindo-Fraga A, Ortiz-Hernández AA, Ramírez-Venegas A, Vázquez RV, Moreno-Espinosa S, Llamosas-Gallardo B, et al. Clinical characteristics and outcomes of influenza and other influenza-like illnesses in Mexico City. Int J Infect Dis. 2013;17:e510–517.
Shao X, Guo X, Esper F, Weibel C, Kahn JS. Seroepidemiology of group I human coronaviruses in children. J Clin Virol. 2007;40:207–13.
Fernandes-Matano L, Monroy-Muñoz IE, Angeles-Martínez J, Sarquiz-Martinez B, Palomec-Nava ID, Pardavé-Alejandre HD, et al. Prevalence of non-influenza respiratory viruses in acute respiratory infection cases in Mexico. PLoS ONE. 2017;12:e0176298.
Wong-Chew RM, García-León ML, Noyola DE, Perez Gonzalez LF, Gaitan Meza J, Vilaseñor-Sierra A, et al. Respiratory viruses detected in Mexican children younger than 5 years old with community-acquired pneumonia: a National multicenter study. Int J Infect Dis. 2017;62:32–8.
Killerby ME, Biggs HM, Haynes A, Dahl RM, Mustaquim D, Gerber SI, et al. Human coronavirus circulation in the united States 2014–2017. J Clin Virol. 2018;101:52–6.
Zhang H-P, Sun Y-L, Wang Y-F, Yazici D, Azkur D, Ogulur I, et al. Recent developments in the immunopathology of COVID-19. Allergy. 2023;78:369–88.
Jafari M, Asli S, Moghbeli F, Fesharaki MG, Hajiahmadi N, Mojtahedzadeh F, et al. Persistence of SARS-CoV-2-antibodies against N, S and RBD after natural infection. Iran J Microbiol. 2023;15:803–10.
Shrock E, Fujimura E, Kula T, Timms RT, Lee I-H, Leng Y, et al. Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity. Science. 2020;370:eabd4250.
Boechat JL, Chora I, Morais A, Delgado L. The immune response to SARS-CoV-2 and COVID-19 immunopathology – Current perspectives. Pulmonology. 2021;27:423–37.
Gusev E, Sarapultsev A, Solomatina L, Chereshnev V. SARS-CoV-2-Specific immune response and the pathogenesis of COVID-19. IJMS. 2022;23:1716.
Lee WS, Wheatley AK, Kent SJ, DeKosky BJ. Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies. Nat Microbiol. 2020;5:1185–91.
Nakayama EE, Shioda T. SARS-CoV-2 related Antibody-Dependent enhancement phenomena in vitro and in vivo. Microorganisms. 2023;11:1015.
Puhach O, Meyer B, Eckerle I. SARS-CoV-2 viral load and shedding kinetics. Nat Rev Microbiol. 2023;21:147–61.
Ke R, Martinez PP, Smith RL, Gibson LL, Mirza A, Conte M, et al. Daily longitudinal sampling of SARS-CoV-2 infection reveals substantial heterogeneity in infectiousness. Nat Microbiol. 2022;7:640–52.
Rydyznski Moderbacher C, Ramirez SI, Dan JM, Grifoni A, Hastie KM, Weiskopf D, et al. Antigen-Specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity. Cell. 2020;183:996–e101219.
Zhao H, Cai Z, Rao J, Wu D, Ji L, Ye R, et al. SARS-CoV-2 RNA stabilizes host mRNAs to elicit Immunopathogenesis. Mol Cell. 2024;84:490–e5059.
Zhang Y, Zeng G, Pan H, Li C, Hu Y, Chu K, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021;21:181–92.
Ramasamy MN, Minassian AM, Ewer KJ, Flaxman AL, Folegatti PM, Owens DR, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet. 2021;396:1979–93.
Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383:2603–15.
Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021;397:671–81.
Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384:403–16.
Keech C, Albert G, Cho I, Robertson A, Reed P, Neal S, et al. Phase 1–2 trial of a SARS-CoV-2 Recombinant Spike protein nanoparticle vaccine. N Engl J Med. 2020;383:2320–32.
Sadoff J, Le Gars M, Shukarev G, Heerwegh D, Truyers C, de Groot AM, et al. Interim results of a phase 1-2a trial of Ad26.COV2.S Covid-19 vaccine. N Engl J Med. 2021;384:1824–35.
Bai S, Zhou S, Zhang J, Chen W, Lv M, Wang J, et al. Immunogenicity and safety of different combinations involving a third booster dose of SARS-CoV-2 inactivated vaccine, inactivated quadrivalent influenza vaccine, and 23-valent Pneumococcal polysaccharide vaccine in adults aged ≥ 60 years: a phase 4, randomized, open-label study. Front Immunol. 2024;15:1437267.
Zhang Z, Mateus J, Coelho CH, Dan JM, Moderbacher CR, Gálvez RI, et al. Humoral and cellular immune memory to four COVID-19 vaccines. Cell. 2022;185:2434–e245117.
Röltgen K, Nielsen SCA, Silva O, Younes SF, Zaslavsky M, Costales C, et al. Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination. Cell. 2022;185:1025–e104014.
Uzun O, Akpolat T, Varol A, Turan S, Bektas SG, Cetinkaya PD, et al. COVID-19: vaccination vs. hospitalization. Infection. 2022;50:747–52.
Agrawal U, Bedston S, McCowan C, Oke J, Patterson L, Robertson C, et al. Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters: pooled analysis of National prospective cohort studies of 30 million individuals in England, Northern Ireland, Scotland, and Wales. Lancet. 2022;400:1305–20.
Permpikul P, Tongyoo S, Chaimayo C, Kanpai P, Virat J, Virat S, et al. Anti-SARS-CoV-2 antibody among SARS-CoV-2 vaccinated vs post-infected blood donors in a tertiary hospital, Bangkok, Thailand. PLoS One. 2023;18:e0285737.
Guzmán-Martínez O, Guardado K, de Guevara EL, Navarro S, Hernández C, Zenteno-Cuevas R, et al. IgG antibodies generation and side effects caused by Ad5-nCoV vaccine (CanSino Biologics) and BNT162b2 vaccine (Pfizer/BioNTech) among Mexican population. Vaccines. 2021;9:999.
Cruz-Cardenas JA, Gutierrez M, López-Arredondo A, Castañeda-Delgado JE, Rojas-Martinez A, Nakamura Y, et al. A pseudovirus-based platform to measure neutralizing antibodies in Mexico using SARS-CoV-2 as proof-of-concept. Sci Rep. 2022;12:17966.
Fernandes-Matano L, Salas-Lais AG, Grajales-Muñiz C, Hernández-Ávila M, Garfias-Becerra YO, Rodríguez-Sepúlveda MC, et al. Longevity and neutralizing capacity of IgG antibodies against SARS-CoV-2 generated by the application of BNT162b2, AZD1222, Convidecia, sputnik V, and coronavac vaccines: a cohort study in the Mexican population. Microbiol Spectr. 2023;11:e0237622.
Morales-Núñez JJ, Muñoz-Valle JF, Machado-Sulbarán AC, Díaz-Pérez SA, Torres-Hernández PC, Panduro-Espinoza BV, et al. Comparison of three different COVID-19 vaccine platforms (CoronaVac, BTN162b2, and Ad5-nCoV) in individuals with and without prior COVID-19: reactogenicity and neutralizing antibodies. Immunol Lett. 2022;251–252:20–8.
Garza-Silva A, Rivera-Salinas D, Rivera-Cavazos A, Fernández-Chau IF, Cepeda-Medina AB, Morales-Rodríguez DP, et al. Effectiveness of different booster vaccine combinations against SARS-CoV-2 during a six-month follow-up in Mexico and Argentina. Front Immunol. 2024;15:1403784.
Fernandes-Matano L, Salas-Lais AG, Grajales-Muñiz C, Hernández-Ávila M, Garfias-Becerra YO, Rodríguez-Sepúlveda MC, et al. Longevity and neutralizing capacity of IgG antibodies against SARS-CoV-2 generated by the application of BNT162b2, AZD1222, Convidecia, sputnik V, and coronavac vaccines: a cohort study in the Mexican population. Microbiol Spectr. 2023;11:e02376–22.
Hillus D, Schwarz T, Tober-Lau P, Vanshylla K, Hastor H, Thibeault C, et al. Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study. Lancet Respir Med. 2021;9:1255–65.
Benning L, Töllner M, Hidmark A, Schaier M, Nusshag C, Kälble F, et al. Heterologous ChAdOx1 nCoV-19/BNT162b2 Prime-Boost vaccination induces strong humoral responses among health care workers. Vaccines (Basel). 2021;9:857.
Goel RR, Painter MM, Apostolidis SA, Mathew D, Meng W, Rosenfeld AM, et al. mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern. Science. 2021;374:abm0829.
Stamatatos L, Czartoski J, Wan Y-H, Homad LJ, Rubin V, Glantz H, et al. mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection. Science. 2021;372:1413–8.
Gaebler C, Wang Z, Lorenzi JCC, Muecksch F, Finkin S, Tokuyama M, et al. Evolution of antibody immunity to SARS-CoV-2. Nature. 2021;591:639–44.